Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adult and adolescents (≥12 years to \<18 years, and weighing ≥40 kg).~2. Chronic AD (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit.~3. Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit.~4. Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit~5. ≥10% body surface area (BSA) of AD involvement at the baseline visit.~6. History of inadequate response to treatment with topical medications.~Exclusion Criteria:~1. Participation in a prior lebrikizumab clinical study.~2. Treatment with the following prior to the baseline visit:~   1. An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer.~  2. Dupilumab within 8 weeks.~  3. B-cell-depleting biologics, including to rituximab, within 6 months.~  4. Other biologics within 5 half-lives (if known) or 16 weeks, whichever is longer.~3. Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study.~4. Uncontrolled chronic disease that might require bursts of oral corticosteroids.~5. Evidence of active acute or chronic hepatitis~6. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.~7. History of malignancy, including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.~8. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lebrikizumab + Topical Corticosteroid (Type: EXPERIMENTAL): 500 mg Lebrikizumab (2 x 250 mg) subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 followed by a single injection of 250 mg Lebrikizumab every 2 weeks (Q2W) from Week 4 until Week 14.~Topical corticosteroid (TCS) will be initiated at Baseline in all participants and may be tapered or stopped, or restarted as needed, based on treatment response.
- Placebo + Topical Corticosteroid (Type: PLACEBO_COMPARATOR): Two placebo subcutaneous (SC) injections as a loading dose at Baseline and Week 2 followed by a single injection of placebo every Q2W from Week 4 until Week 14.~TCS will be initiated at Baseline in all participants and may be tapered or stopped, or restarted as needed, based on treatment response

Based on this trial design, predict the completion outcome and termination type (if applicable).